Teva Pharmaceutical Industries will advance its anti-IL-15 antibody, TEV-408, into a Phase 2b vitiligo study.
The company expects to begin the trial in the fourth quarter of 2026.
The decision follows positive results from an ongoing Phase 1b open-label trial in adults with active or stable non-segmental vitiligo.
Nearly 75% of Phase 1b participants reported improvements in facial vitiligo.
The trial also demonstrated enhanced skin pigmentation and a favorable safety profile with no observed safety signals.
Teva scheduled an investor call and webcast to discuss the asset's role in its immunology pipeline.